54 related articles for article (PubMed ID: 7988303)
1. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.
Gutniak MK; Linde B; Holst JJ; Efendić S
Diabetes Care; 1994 Sep; 17(9):1039-44. PubMed ID: 7988303
[TBL] [Abstract][Full Text] [Related]
2. Associations between feeding and glucagon-like peptide-2 in healthy ponies.
Sibthorpe PEM; Fitzgerald DM; Sillence MN; de Laat MA
Equine Vet J; 2024 Mar; 56(2):309-317. PubMed ID: 37705248
[TBL] [Abstract][Full Text] [Related]
3. Normal meal tolerance test is preferable to the glucagon stimulation test in patients with type 2 diabetes that are not in a hyperglycemic state: Comparison with the change of C-peptide immunoreactivity.
Fujioka Y; Okura T; Sumi K; Matsumoto K; Shoji K; Nakamura R; Matsuzawa K; Izawa S; Kato M; Taniguchi S; Yamamoto K
J Diabetes Investig; 2018 Mar; 9(2):274-278. PubMed ID: 28494143
[TBL] [Abstract][Full Text] [Related]
4. Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?
Home PD
Diabetes Obes Metab; 2015 Nov; 17(11):1011-20. PubMed ID: 26041603
[TBL] [Abstract][Full Text] [Related]
5. The protective effect of the Mediterranean diet on endothelial resistance to GLP-1 in type 2 diabetes: a preliminary report.
Ceriello A; Esposito K; La Sala L; Pujadas G; De Nigris V; Testa R; Bucciarelli L; Rondinelli M; Genovese S
Cardiovasc Diabetol; 2014 Nov; 13():140. PubMed ID: 25407792
[TBL] [Abstract][Full Text] [Related]
6. Acute sleep deprivation delays the glucagon-like peptide 1 peak response to breakfast in healthy men.
Benedict C; Barclay JL; Ott V; Oster H; Hallschmid M
Nutr Diabetes; 2013 Jun; 3(6):e78. PubMed ID: 23797385
[TBL] [Abstract][Full Text] [Related]
7. Effects of Low-Dose Glucagon on Subcutaneous Insulin Absorption in Pigs.
Teigen IA; Åm MK; Riaz M; Christiansen SC; Carlsen SM
Curr Ther Res Clin Exp; 2024; 100():100736. PubMed ID: 38511103
[TBL] [Abstract][Full Text] [Related]
8. Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives.
Ding B; Zhu Z; Guo C; Li J; Gan Y; Yu M
Acta Pharm Sin B; 2024 May; 14(5):2006-2025. PubMed ID: 38799624
[TBL] [Abstract][Full Text] [Related]
9. L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease.
Elabi OF; Davies JS; Lane EL
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830228
[TBL] [Abstract][Full Text] [Related]
10. Normalisation of glucose metabolism by exendin-4 in the chronic phase after stroke promotes functional recovery in male diabetic mice.
Augestad IL; Dekens D; Karampatsi D; Elabi O; Zabala A; Pintana H; Larsson M; Nyström T; Paul G; Darsalia V; Patrone C
Br J Pharmacol; 2022 Feb; 179(4):677-694. PubMed ID: 33973246
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 Receptor Signaling in Astrocytes Regulates Fatty Acid Oxidation, Mitochondrial Integrity, and Function.
Timper K; Del Río-Martín A; Cremer AL; Bremser S; Alber J; Giavalisco P; Varela L; Heilinger C; Nolte H; Trifunovic A; Horvath TL; Kloppenburg P; Backes H; Brüning JC
Cell Metab; 2020 Jun; 31(6):1189-1205.e13. PubMed ID: 32433922
[TBL] [Abstract][Full Text] [Related]
12. Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin.
Okajima F; Emoto N; Kato K; Sugihara H
J Atheroscler Thromb; 2017 Feb; 24(2):157-168. PubMed ID: 27397060
[TBL] [Abstract][Full Text] [Related]
13. Liraglutide improves pancreatic Beta cell mass and function in alloxan-induced diabetic mice.
Tamura K; Minami K; Kudo M; Iemoto K; Takahashi H; Seino S
PLoS One; 2015; 10(5):e0126003. PubMed ID: 25938469
[TBL] [Abstract][Full Text] [Related]
14. In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis.
Plum A; Jensen LB; Kristensen JB
J Pharm Sci; 2013 Aug; 102(8):2882-8. PubMed ID: 23853127
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
He YL
Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
[TBL] [Abstract][Full Text] [Related]
16. Combining basal insulin analogs with glucagon-like peptide-1 mimetics.
Perfetti R
Diabetes Technol Ther; 2011 Sep; 13(9):873-81. PubMed ID: 21711120
[TBL] [Abstract][Full Text] [Related]
17. Exenatide once weekly: clinical outcomes and patient satisfaction.
Jose B; Tahrani AA; Piya MK; Barnett AH
Patient Prefer Adherence; 2010 Sep; 4():313-24. PubMed ID: 20859458
[TBL] [Abstract][Full Text] [Related]
18. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
Grieve DJ; Cassidy RS; Green BD
Br J Pharmacol; 2009 Aug; 157(8):1340-51. PubMed ID: 19681866
[TBL] [Abstract][Full Text] [Related]
19. Alpha cell function in health and disease: influence of glucagon-like peptide-1.
Dunning BE; Foley JE; Ahrén B
Diabetologia; 2005 Sep; 48(9):1700-13. PubMed ID: 16132964
[TBL] [Abstract][Full Text] [Related]
20. Control of blood glucose by novel GLP-1 delivery using biodegradable triblock copolymer of PLGA-PEG-PLGA in type 2 diabetic rats.
Choi S; Baudys M; Kim SW
Pharm Res; 2004 May; 21(5):827-31. PubMed ID: 15180341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
